Home › Companies › AbCellera Biologics Inc. › 2024-2025
Compiled from SEC Form N-PX filings and AbCellera Biologics Inc.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 12, 2025: 4 items on AbCellera Biologics Inc.’s Form 8-K, filed June 13, 2025: 2 approved · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore AbCellera Biologics Inc. in the interactive database Compare manager voting policies
These tallies are AbCellera Biologics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Carl L. G. Hansen, Ph.D. | 141,233,414 | 444,265 | 6,760,498 | -- | -- | 99.6% | Not verified | — |
| Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D. | 121,224,143 | 417,794 | 26,796,240 | -- | -- | 99.6% | Not verified | — |
| 2. Proposal 2 | 183,078,982 | 678,941 | 241,151 | -- | -- | 99.6% | Approved | — |
| 3. Proposal 3 | 131,605,595 | 16,469,354 | 363,228 | -- | -- | 89% | Approved | — |
Source: AbCellera Biologics Inc., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.
Each item below shows how the 102 asset managers that disclosed a AbCellera Biologics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AbCellera Biologics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our Board of Directors, to serve until the 2028 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Carl L.G. Hansen
AbCellera Biologics Inc.’s own tally for this item (“Elect Director: Carl L. G. Hansen, Ph.D.”): 141,233,414 for, 444,265 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 14,428,367 for, 6,133,665 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 13,361,096 | 0 | 0 | 0 | For |
| Virtus | 0 | 0 | 0 | 6,133,665 | Withhold |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 112,543 | 0 | 0 | 0 | For |
| American Century | 84,633 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 39,000 | 0 | 0 | 0 | For |
| State Street | 30,343 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,643 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 12,040 | 0 | 0 | 0 | For |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our Board of Directors, to serve until the 2028 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Michael Hayden
AbCellera Biologics Inc.’s own tally for this item (“Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D.”): 121,224,143 for, 417,794 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 14,128,165 for, 6,433,867 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 13,361,096 | 0 | 0 | 0 | For |
| Virtus | 0 | 0 | 0 | 6,133,665 | Withhold |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 0 | 0 | 0 | 112,543 | Withhold |
| American Century | 0 | 0 | 0 | 84,633 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 39,000 | Withhold |
| State Street | 0 | 0 | 0 | 30,343 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 21,643 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 12,040 | Withhold |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
Combines 8 wordings of this item as funds reported it.
55% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 13,361,096 | 0 | 0 | Against |
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 112,543 | 0 | 0 | 0 | For |
| American Century | 84,633 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 39,000 | 0 | 0 | 0 | For |
| State Street | 30,343 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,643 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 12,040 | 0 | 0 | 0 | For |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
Fund voting reports, all 13 managers: 7,200,936 for, 13,361,096 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 13,361,296 | 0 | 0 | Against |
| BAILLIE GIFFORD & CO LTD | 4,746,417 | 0 | 0 | 0 | For |
| Voya | 4,490,520 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 4,180,768 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 4,105,095 | 0 | 0 | 0 | For |
| NICOLA WEALTH MANAGEMENT LTD. | 1,400,350 | 0 | 0 | 0 | For |
| Lazard | 1,136,653 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,126,915 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 1,027,686 | 0 | 0 | 0 | For |
| BlackRock | 884,484 | 0 | 0 | 0 | For |
| UI BVK Kapitalverwaltungsgesellschaft mbH | 686,573 | 0 | 0 | 0 | For |
| UBS | 0 | 612,878 | 0 | 0 | Against |
| Polar Asset Management Partners Inc. | 459,400 | 0 | 0 | 0 | For |
| Renaissance | 387,548 | 0 | 0 | 0 | For |
| Citadel | 306,280 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 123,308 | 0 | 0 | Mixed |
| PIER 88 INVESTMENT PARTNERS LLC | 243,790 | 0 | 0 | 0 | For |
| Guardian Partners Inc. | 200,450 | 0 | 0 | 0 | For |
| Mediolanum International Funds Ltd | 178,337 | 0 | 0 | 0 | For |
| Allianz | 123,077 | 0 | 0 | 0 | For |
| American Century | 84,633 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 80,000 | 0 | 0 | 0 | For |
| Northern Trust | 75,782 | 0 | 0 | 0 | For |
| Two Sigma | 70,119 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 64,232 | 0 | 0 | 0 | For |
Institutional-manager reports, all 88 managers: 26,631,485 for, 14,109,475 against. Showing the 25 largest; see all in the interactive database.
100% of fund votes cast · no official result
The 3 asset managers below reported 9,803,037 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TD ASSET MANAGEMENT INC | 9,399,486 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 380,111 | 0 | 0 | 0 | For |
| TD Waterhouse Canada Inc. | 23,440 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
The 2 asset managers below reported 33,872 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Green Alpha Advisors, LLC | 33,862 | 0 | 0 | 0 | For |
| Focus Partners Wealth | 10 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
The 13 asset managers below reported 20,562,032 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 13,361,096 | 0 | 0 | 0 | For |
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 112,543 | 0 | 0 | 0 | For |
| American Century | 84,633 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 39,000 | 0 | 0 | 0 | For |
| State Street | 30,343 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,643 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 12,040 | 0 | 0 | 0 | For |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 298,484,664 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 4.48% |
| 2 | Virtus | 2.05% |
| 3 | Vanguard | 0.13% |
| 4 | BlackRock | 0.06% |
| 5 | Federated Hermes | 0.05% |
| 6 | Listed Funds Trust | 0.04% |
| 7 | American Century | 0.03% |
| 8 | Blackstone Alternative Investment Funds | 0.01% |
| 9 | State Street | 0.01% |
| 10 | ETFis Series Trust I | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 4.48% |
| 2 | BAILLIE GIFFORD & CO LTD | 1.59% |
| 3 | Voya | 1.50% |
| 4 | ORBIMED ADVISORS LLC | 1.40% |
| 5 | ArrowMark Colorado Holdings LLC | 1.38% |
| 6 | NICOLA WEALTH MANAGEMENT LTD. | 0.47% |
| 7 | Lazard | 0.38% |
| 8 | Novo Holdings A/S | 0.38% |
| 9 | BAILLIE GIFFORD OVERSEAS LTD | 0.34% |
| 10 | BlackRock | 0.30% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Carl L.G. Hansen, Ph.D. | 21.23% | DEF14A |
| Thermopylae Holdings Ltd. | 18.81% | DEF14A |
| Baker Bros. Advisors LP | 9.22% | DEF14A |
| Véronique Lecault, Ph.D. | 4.24% | DEF14A |
| Andrew Booth | 2.04% | DEF14A |
| BlackRock | 1.20% | 13F |
| Two Sigma | 1.05% | 13F |
| Renaissance Technologies | 0.97% | 13F |
| Tryn Stimart | 0.90% | DEF14A |
| Citadel Advisors | 0.67% | 13F |
Percentages above are of 298,484,664 shares outstanding, as reported by AbCellera Biologics Inc. on its Form 10-Q dated May 5, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AbCellera Biologics Inc.’s 10-Q dated May 5, 2025. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At AbCellera Biologics Inc.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 102 asset managers reported how they voted in their SEC Form N-PX filings, covering 186 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. AbCellera Biologics Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — the reporting funds and managers cast 55% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
AbCellera Biologics Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Download data (CSV): ballot items · votes by manager · column guide.